Urologic referral, in particular, is recommended for men who, in the first year of T treatment, have a confirmed increase in PSA values of 1.4 ng/mL or a confirmed absolute value of 4.0 ng/mL (or 3 ng/mL in men at high risk of prostate cancer) [16]. This evidence concerns the gene KLK3 and prostate carcinoma.